We recently published a list of Why These 10 Firms Soared on Monday. In this article, we are going to take a look at where BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stands against other Monday’s best performers.

The stock market kicked off the trading week on a negative note as investors sold off on a new round of uncertainties from President Donald Trump’s tariff policies.

The Nasdaq fell by 0.74 percent, while the S&P 500 dropped 0.64 percent and the Dow Jones was down by 0.24 percent.

Over the weekend, Trump told reporters that the US was negotiating with many countries, “but at the end of this, I’ll set my own deals — because I set the deal, they don’t set the deal.”

He added that he had no intentions to talk with Chinese President Xi Jinping, dampening hopes of a potential negotiation between the two of the world’s largest economies.

Beyond the major indices, 10 companies stood out with strong gains amid a flurry of fresh developments. In this article, we name Monday’s 10 best performers and detail the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

A scientist in a lab coat observing a line of medicine pills in a container.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals jumped by 23.52 percent on Monday, a second straight day, ending the day at $11.03 apiece following its impressive earnings performance in the first quarter, coupled with a highly optimistic outlook for the rest of the year.

In a statement, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it swung to a net income of $32,000 from a net loss of $35.38 million in the same period a year earlier as revenues jumped by 57 percent to $145.5 million from $92.76 million year-on-year, thanks to the strong performance of its hereditary angioedema treatment, Orladeyo.

Looking ahead, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it now expects to be fully profitable for the rest of the year ahead of its original target.

Revenues from Orladeyo alone were expected to settle between $580 million and $600 million, higher than the $535 million to $550 million targeted previously.

Full-year operating expenses were also targeted to settle only between $440 million and $450 million, from the previous $425 million to $435 million.

Overall, BCRX ranks 2nd on our list of Monday’s best performers. While we acknowledge the potential of BCRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BCRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

Story Continues

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments